

HELSINN HEALTHCARE AT THE 14th EUROPEAN CANCER CONFERENCE (ECCO) Barcelona, 23-27 September 2007



LUGANO, SWITZERLAND, October 24th, 2007– Helsinn Healthcare participated in the leading 2007 European conference on cancer, the 14th European Cancer Conference (ECCO), held in Barcelona, Spain from 23rd to 26th September, which registered an attendance of over 13'000 participants.

The latest scientific advances in the cancer field were presented and it was emphasized how important it is to implement these in clinical practice.

The same principle inspired Helsinn's satellite Symposium, "Creating real benefit for patients at risk of nausea and vomiting: Palonosetron – from bench to bedside", where new information on pharmacological differentiation was the starting point for the presentation of new clinical data and of those related to the quality of life, as further confirmation of, but not only, the clinical benefit associated with palonosetron (Aloxi®).

Official ECCO 14 Sponsored Satellite Symposium

25th September, 2007
Room 114
6.15 pm – 7.45 pm

Creating Real Benefit for Patients at Risk of Nausea and Vomiting: Palonosetron – from Bench to Bedside

CHAIRMAN
Steven Grunberg, MD
University of Vermont, Burlington, USA

- ▶ *Camilo Rojas, PhD*
MGI PHARMA, Baltimore, USA
Understanding the molecular basis of palonosetron's long lasting action
- ▶ *Steven Grunberg, MD*
University of Vermont, Burlington, USA
Role of palonosetron in enhancing antiemetic prophylaxis
- ▶ *Giovanni Rosti, MD*
Medical Oncology Department, Treviso Hospital, Italy
Optimal management of cancer patient from the first stages of the disease

This scientific event met considerable success due to both the novelty of the scientific data presented and to the human message conveyed.

Cancer patients represent the focal point of a global approach where basic research integrates with clinical research and with aspects linked to the quality of life.

Helsinn also took active part in the exhibition area with a booth which registered over 1'000 visitors during the 3-day event, confirming the strong interest in Helsinn's products.

Helsinn's worldwide consolidated network of partners for Palonosetron and Gelclair also played an important role in communicating with the visitors.

Two scientific posters were presented on 26th September:

"Oral palonosetron (PALO) is as effective as intravenous PALO: a phase III dose ranging trial in patients receiving moderately emetogenic chemotherapy."

S. Grunberg, D. Voisin, M. Zufferli, G. Piaraccini

"High dose palonosetron does not alter ECG parameters including QTc interval in healthy subjects: results of a dose-response, double-blind, randomized, parallel E14 study of palonosetron vs. moxifloxacin or placebo."

J. Morganroth, S. Parisi, C. Moresino, M. Thorn, M.T. Cullen

There was particular interest in the study on QTc which represents a further step in differentiation in terms of safety compared to the old 5-HT₃.

About Chemotherapy-Induced Nausea and Vomiting (CINV)

CINV is estimated to potentially affect 85% of cancer patients undergoing chemotherapy and can result in a delay or discontinuation of chemotherapy treatments. The supportive care area is becoming of paramount importance to help patients deal with adverse events of anticancer therapies. With good supportive care drugs, cancer patients are able to tolerate the anti-cancer treatment to a greater extent, improving their chances of completing their treatment course successfully with a better quality of life.

About Aloxi[®]

Aloxi[®] is a selective 5-HT₃-receptor antagonist, developed for the prevention of CINV, with a long half-life of 40 hours and at least 30 times higher receptor binding affinity than currently available compounds. Since its availability in USA in September 2003, there have been over 6.9 million successful uses of Aloxi[®]. The product showed to be effective in preventing both acute and delayed CINV in patients receiving emetogenic chemotherapies. For more information about this product please visit our website: www.aloxi.com.



About HELSINN HEALTHCARE

HELSINN HEALTHCARE SA is a privately owned pharmaceutical group with headquarters in Switzerland and is the worldwide licensor of Aloxi[®]. HELSINN's core business is the licensing of pharmaceuticals in niche therapeutic areas. The company's business strategy is to in-license early-stage new chemical entities and complete their development from the performance of pre-clinical/clinical studies and CMC development to the attainment of market approvals in strategic markets (U.S. and Europe). HELSINN's products are eventually out-licensed to its marketing partners for distribution. The active pharmaceutical ingredients and the finished dosage forms are manufactured at HELSINN's cGMP facilities and supplied worldwide to its customers. For more information about HELSINN, please visit www.helsinn.com.

Contact person HELSINN:

Paolo Ferrari - Head of Marketing – Oncology and Supportive Care

Tel: +41 91-985-21-21.

info-hhc@helsinn.com